Accelerating Oncology Prior Authorization with Da Vinci PAS

Klivira's platform leverages Da Vinci PAS to transform oncology prior authorization, streamlining the complex process of securing approvals for cancer treatments. This integration provides a standardized, efficient pathway for high-volume PA events in oncology care.

Revenue cycle leaders and prior authorization coordinators in oncology face unique challenges: frequent regimen changes, high-cost biologics, and urgent treatment timelines. Traditional manual or portal-based PA processes often introduce delays, impacting patient care and revenue integrity. Adopting standards like Da Vinci PAS is crucial for modernizing this critical workflow.

The Critical Need for Da Vinci PAS in Oncology

Oncology prior authorization is among the most demanding in healthcare, characterized by high-cost biologics, intricate chemotherapy regimens, and frequent treatment modifications. The HL7 Da Vinci Project, particularly the Da Vinci PAS implementation guide, offers a standardized FHIR-based approach to automate and accelerate these critical PA workflows, addressing the unique operational constraints of cancer care.

High-Volume Prior Authorization Triggers in Oncology

J-code chemotherapy and biologic infusions, including immunotherapies and targeted therapies.
Advanced imaging for staging and surveillance, such as PET/CT and tumor-specific molecular imaging.
Radiation oncology procedures, including IMRT, IGRT, SBRT, and proton-beam therapy.
Genetic and molecular testing for treatment selection and risk stratification.
Supportive care medications like growth factors (G-CSF, ESAs) and antiemetics, often integral to complex regimens.

Standardizing Oncology Documentation with Da Vinci DTR

Oncology PA relies heavily on detailed clinical documentation, often guided by NCCN Clinical Practice Guidelines and the NCCN Drugs & Biologics Compendium. Da Vinci DTR (Documentation Templates and Rules) facilitates the structured assembly of required data—such as pathology reports, molecular markers (e.g., ER/PR/HER2, EGFR/ALK/PD-L1), and performance status (ECOG/Karnofsky)—directly from the EMR, replacing cumbersome PDF attachments with FHIR resources for more efficient payer review.

Navigating Medical and Pharmacy Benefit PAs for Oncology Drugs

Oncology drug PAs are complicated by the split between medical benefit (IV infusions, J-codes) and pharmacy benefit (oral oncolytics). Klivira's platform, leveraging Da Vinci PAS for medical benefit and integrating with ePA partners like CoverMyMeds or Surescripts for pharmacy benefit, ensures appropriate routing. This dual capability is essential for managing the diverse PA pathways for agents like Gleevec or Tagrisso (pharmacy) versus IV immunotherapies (medical).

Klivira's Da Vinci PAS Implementation for Oncology Workflows

NCCN-compendium-aware policy logic to surface documentation requirements per regimen and tumor type at the point of order entry.
Regimen-level PA workflow that bundles related components (e.g., chemo + targeted therapy) into a single submission where supported by the payer.
Automated medical-vs-pharmacy benefit routing for seamless management of oral and IV oncology medications.
Concurrent PA tracking for the numerous PA events per patient across diagnosis, treatment changes, and supportive care.
Integration with peer-to-peer scheduling to expedite clinical-necessity reviews for complex oncology cases.

Future-Proofing Oncology PA with FHIR and CMS Mandates

The transition to FHIR-based prior authorization, accelerated by initiatives like Da Vinci PAS and regulatory mandates such as CMS-0057-F, is critical for oncology. Klivira's platform is built to align with these evolving standards, ensuring that clinics and health systems can meet future compliance requirements and leverage the benefits of standardized, automated PA processes for Medicare Advantage, Medicaid managed care, and other impacted plans.

Frequently asked questions

How does Klivira handle the frequent regimen changes in oncology that trigger new PAs?

Klivira's platform is designed for concurrent PA tracking, allowing for the management of multiple active authorizations per patient. For oncology, this means new PA cycles triggered by regimen changes, toxicity, or progression are handled efficiently, maintaining a clear audit trail for each modification.

Can Klivira integrate with my EMR to pull oncology-specific clinical data for Da Vinci DTR?

Yes, Klivira offers robust EMR integration, including SMART on FHIR capabilities, to pull critical oncology data. This enables automated population of Da Vinci DTR questionnaires with details like pathology reports, molecular markers, and performance status directly from your EMR, reducing manual data entry.

How does Da Vinci PAS improve turnaround times for oncology PAs, especially for urgent cases?

By submitting structured FHIR resources instead of unstructured PDFs, Da Vinci PAS enables faster payer-side automated review. This standardization, combined with Klivira's efficient routing and status tracking, helps accelerate decisions, particularly crucial for urgent oncology treatments where delays can impact patient outcomes.

What if a payer isn't fully Da Vinci PAS-conformant yet for oncology services?

Klivira's platform offers intelligent routing. For payers not yet fully PAS-conformant, we seamlessly fall back to established channels like X12 278 EDI, direct payer portals (e.g., Availity, UHCprovider.com), or even fax, ensuring that your oncology PA submissions continue without interruption while payers transition to FHIR.

How does Klivira ensure compliance with NCCN guidelines for oncology prior authorizations?

Klivira's NCCN-compendium-aware policy logic is embedded in our platform. This helps ensure that submitted documentation aligns with payer policies that reference NCCN guidelines, reducing denials due to insufficient clinical evidence or off-label use without appropriate compendium support.